Waltham, MA (PRWEB) October 21, 2008
EyeGate Pharma, a specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics to treat serious ocular diseases, today announced that Stephen From, President and Chief Executive Officer of EyeGate Pharma, will present a corporate overview at the 7th Annual BIO Investor Forum and the Acumen BioFin Rodman and Renshaw 10th Annual Healthcare Conference. Representatives from the Company will also attend the American Academy of Ophthalmology's (AAO) and European Society of Ophthalmology's (SOE) 2008 Joint Meeting.
Mr. From will be available for one-on-one meetings with potential investors during both investor conferences:
The 7th Annual BIO Investor Forum will take place from October 29-31, 2008, in San Francisco, CA. Mr. From will present a corporate overview on Thursday, October 30 at 2:45PM in the Napa room. For more information, please visit http://www.investorforum.bio.org/opencms/bif/2008/.
The Acumen BioFin Rodman and Renshaw 10th Annual Healthcare Conference will take place from November 10-12, 2008 in New York, NY. Mr. From will present a corporate overview on November 10, 2008 at 11:10AM in the Louis Room (4th floor). For more information, please visit http://www.rodmanandrenshaw.com/conferences?id=19.
In addition, EyeGate representatives will be attending the American Academy of Ophthalmology's (AAO) and European Society of Ophthalmology's (SOE) 2008 Joint Meeting taking place from November 8-11, 2008 in Atlanta, GA. On Saturday, November 8, the Company will host a cocktail reception at the Hilton Garden Inn Atlanta in the Atlantic Room from 5:00-6:30PM. To RSVP for this event, please contact us at the information below. For more information on the conference, please visit http://www.aao.org/meetings/annual_meeting/.
About EyeGate Pharma
EyeGate Pharma has recently initiated a Phase II clinical study in acute anterior uveitis designed to assess the safety and tolerability of the non-invasive EyeGate® II Ocular Drug Delivery System and plans to initiate an additional Phase II clinical trial with EGP-437 in dry eye later in 2008. EyeGate was founded in 1998 with technology licensed from Bascom Palmer Eye Institute at the
University of Miami. EyeGate's transscleral (white membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was developed to safely deliver a wide range of
therapeutics to both the anterior (front) and posterior (back) chambers of the eye. For more information, please visit http://www.eyegatepharma.com.